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Abstract
It is well documented that angiotensin (Ang) II contributes to kidney disease progression.
The protease prolyl carboxypeptidase (PRCP) is highly expressed in the kidney and may
be renoprotective by degrading Ang II to Ang-(1-7). The aim of the study was to investigate
whether renal PRCP protein expression and activity are altered in two-kidney, one-clip
(2K1C) Goldblatt hypertensive mice. Left renal artery was constricted by using 0.12 mm silver clips. Blood pressure was measured using telemetry over the eleven weeks of study period and revealed an immediate increase in 2K1C animals during the first week of clip
placement which was followed by a gradual decrease to baseline blood pressure. Similarly,
urinary albumin excretion was significantly increased one week after 2K1C and returned to
baseline levels during the following weeks. At 2 weeks and at the end of the study, renal pathologies were exacerbated in the 2K1C model as revealed by a significant increase in
mesangial expansion and renal fibrosis. Renal PRCP expression and activity were significantly reduced in clipped kidneys. Immunofluorescence revealed the loss of renal tubular
PRCP but not glomerular PRCP. In contrast, expression of prolyl endopeptidase, another
enzyme capable of converting Ang II into Ang-(1-7), was not affected, while angiotensin
converting enzyme was elevated in unclipped kidneys and renin was increased in clipped
kidneys. Results suggest that PRCP is suppressed in 2K1C and that this downregulation
may attenuate renoprotective effects via impaired Ang II degradation by PRCP.

Introduction
There are 26 million adults with chronic kidney disease (CKD) in the United States and the
number of those affected continues to increase [1]. The activation of the renin angiotensin system (RAS) and the elevated formation of the vasoconstrictor angiotensin (Ang) II both contribute to renal pathophysiology by stimulating pathways that lead to aldosterone release,
water retention, vasoconstriction, fibrogenesis, and inflammation [2–4]. There is emerging evidence that Ang II and Ang-(1–7) have counter-regulatory roles. While Ang II functions as a
potent vasoconstrictor and is implicated in the pathophysiology of various kidney diseases,
Ang-(1–7) protects against renal damage and cardiovascular disease (5–8). Indeed, treatment
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or chronic infusion with Ang-(1–7) results in vasodilation, antiproliferation, antihypertrophy
and antifibrosis mediated through binding of the heptapetide to the Mas receptor [5–12]. Angiotensin converting enzyme 2 (ACE2) converts Ang II to Ang-(1–7) [13]. ACE2 has been
shown to be cardio- and renoprotective in various animal models of metabolic and cardiovascular diseases [14–26]. Notably, ACE2 deficient mice exhibit a normal phenotype at baseline as
well as unaltered levels of Ang II and Ang-(1–7) in the kidney, heart, and plasma suggesting
the presence of alternative pathways for peptide formation [5,14,17,27–32].
In addition to ACE2, Ang-(1–7) can be formed by prolyl endopeptidase (PREP) [32,33],
prolyl carboxypeptidase (PRCP) [34], neprilysin (NEP) [33,35], thimet oligopeptidase [36] and
neurolysin [36]. Recent work in our laboratory using novel mass spectrometric techniques for
the characterization of RAS enzymes demonstrated that both ACE2 and PRCP contribute
equally to renal Ang II degradation to Ang-(1–7) [37,38]. PRCP, also known as angiotensinase
C (EC 3.4.16.2), was first isolated from human kidney, urine and leucocytes [39]. PRCP is an
exopeptidase that catalyzes the cleavage of C-terminal peptide bonds with proline in the penultimate position. Different from ACE2, PRCP accepts also Ang III as a substrate producing
Ang-(2–7) [40]. Although the C-terminal peptide sequence of Ang II and Ang III is identical,
PRCP hydrolyzes Ang III faster than Ang II. While not much is known about the biological effects of Ang-(2–7) in humans, Ang III shares similar physiological activities with Ang II suggesting it may be equally or even more important than Ang II in some actions, e.g aldosterone
or vasopressin release and blood pressure regulation [41–45].
The optimal PRCP enzyme activity naturally occurs at acidic pH  6. However, PRCP also
exerts activity at neutral pH [39,46]. PRCP is localized in the kidney to the tubular apical membrane [47]. Originally, PRCP has been identified as soluble and lysosomal enzyme, and recent
studies demonstrated membrane-bound PRCP [34,46–48]. Its known substrates are Ang II,
Ang III, plasma prekallikrein, bradykinin, and α-melanocyte-stimulating hormone, suggesting
a major role of PRCP in the regulation of vascular function, blood pressure, inflammation,
food intake, and angiogenesis [46,49–53]. Indeed, PRCP deficient mice present with vascular
dysfunction, oxidative stress, and reduced body weight [47,49]. A recent study found elevated
plasma PRCP levels in diabetic and obese patients [54]. Additionally, PRCP E112D polymorphisms have been associated with decreased PRCP gene expression, hypertension, and preeclampsia [55,56]. However, the role of PRCP in renal physiology and pathophysiology has not
been investigated before.
Therefore, the effects of chronic renal injury on the expression of PRCP was examined in
clipped and contralateral, unclipped kidneys of mice with renovascular hypertension induced
by clamping of the renal artery [57]. This approach is known as the two-kidney, one-clip
(2K1C) Goldblatt (2K1C) model. The 2K1C model mimics renal artery stenosis in humans
which has been shown to induce secondary hypertension and ischemic changes in the affected
kidney [58]. The studies described herein aid toward dissecting the role of hypertension, hypoperfusion and elevated Ang II levels on renal PRCP in the 2K1C model of
renovascular hypertension.

Materials and Methods
Animals
Male C57BL/6 mice were housed at 22°C under standard 12 hour light/12 hour dark conditions
with ad libitum access to water and standard chow (Harlan Teklad, Madison, WI, USA). All experimental protocols were approved by WSU Animal Care and Use Committee (protocol
number: AUP 937). All surgery was performed under 2% isoflurane anesthesia, and all efforts
were made to minimize pain and suffering.
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Blood pressure, heart rate and locomotor activity measurements using
radiotelemetric probes
Mice were anesthetized with 2% isoflurane. An incision was made along the neck. Using blunt
dissection the left common carotid artery was located followed by clamping and cannulation.
A sterile radiotelemetric catheter, model TA11PA-C10 (Data Sciences International, St Paul,
MN, USA), was inserted into the carotid artery and tied in place. The body of the transmitter
was inserted into a pouch below the skin on the right flank. The skin was closed using 5.0 sterile
sutures (Arosurgical, Newport Beach, CA, USA). Carprofen (5 mg/kg; Sigma-Aldrich,
St. Louis, MO, USA) was given SC immediately and 24 hour later for post-operative analgesia.
Animals were allowed to recover for one week before blood pressure, heart rate and locomotor
activity were recorded.

Goldblatt Two-Kidney, One-Clip (2K1C) Surgery
Mice were anesthetized with 2% isoflurane and the kidney was visualized through a flank incision. A u-shaped silver clip (Exidel SA, Delemont, Switzerland) was inserted onto the left renal
artery leaving a 0.12 mm gap for ischemic blood flow. Carprofen (5 mg/kg, SC) was given immediately and 24 hour later for post-operative analgesia.

Kidney histology and immunohistochemistry
Kidneys were collected from mice anaesthetized by ketamine/xylazine (100:8 mg/kg, I.P.) and
perfused transcardially with cold PBS followed by 4% paraformaldehyde. For histology, paraffin sections (4 μm) were stained with periodic acid-Schiff (PAS) and Masson’s trichrome
(AML Laboratories, Baltimore, MD, USA) and examined under light microscopy. For immunofluorescence, paraffin sections were deparaffinized and incubated at 95°C for 30 min in 10
mM sodium citrate pH 6. Sections were then incubated with 10% horse serum diluted in 0.3%
Triton PBS followed by primary antibody rabbit anti-PRCP (1:50 dilution, Biorbyt cat #
orb13658, San Francisco, CA, USA) and goat anti-nephrin (1:200 dilution, R&D cat # AF3159,
Minneapolis, MN, USA) diluted in 0.1% Triton PBS containing 5% horse serum. Sections were
then incubated with donkey anti-rabbit Alexa-568 (Life Technologies, Grand Island, NY, USA)
or donkey anti-goat Alexa-488 (Jackson ImmunoResearch Laboratories, West Grove, PA,
USA) diluted 1:100. Sections were cover slipped using Vectashield hard set mounting medium
(Vector Laboratories, Burlingame, CA, USA). Images were acquired with an Olympus FV300
confocal microscope (Olympus, Center Valley, PA, USA).

Western Blot
Kidneys were quickly collected, flash frozen in liquid nitrogen and homogenized with 1.4 mm
ceramic beads in complete lysis M-EDTA free buffer (Roche Diagnostics, Mannheim, Germany) supplemented with 2.5 mM PMSF using a Precellys24 bead homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France). Kidney homogenates were centrifuged at 10,000 x
g for 10 minutes at 4°C to remove cellular debris. Total protein content was determined using
bovine serum albumin as standard and BioRad reagent (BioRad, Hercules, CA, USA). Kidney
homogenates (60 μg protein) were loaded to a 10% SDS-PAGE gel and transferred to a 0.2 μm
PVDF membrane (Millipore, Billerica, MA, USA). Membranes were probed with goat antiPRCP (1:500 dilution, Biorbyt cat # orb13658, San Francisco, CA, USA), rabbit anti-PREP
(1:2000 dilution, Abcam cat # ab58995, Cambridge, MA, USA) or goat anti-ACE (1:200, Santa
Cruz Biotechnology, Inc., cat # sc-12184, Dallas, TX, USA) followed by incubation with horseradish peroxidase conjugated donkey anti-rabbit (1:3000 dilution, Abcam) or donkey anti-goat
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(1:5000 dilution, Santa Cruz Biotechnology). Bands were detected using SuperSignal chemiluminescent substrate (Pierce, Rockford, IL, USA) and visualized with a ChemiDoc MP imaging
system (BioRad, Hercules, CA, USA) at ACE 195 kDa, PREP 81 kDa, PRCP 56 kDa. Protein intensity was normalized to ß-actin (Sigma, St. Louis, MO, USA) and analyzed using Imaging
Lab 4.0 software (BioRad, Hercules, CA, USA).

Renal PRCP and renin enzyme activity
Ang-(1–7) formation from Ang II was assessed using matrix assisted laser desorption ionization (MALDI) time-of-flight (TOF) based enzyme assays as previously described with some
modifications [37,38]. For the in situ PRCP enzyme assays, consecutive tissue sections (12 μm)
were prepared from fresh frozen kidneys and incubated with 1 mM Ang II at 37°C for 5 min.
For the in vitro PRCP enzyme assays, kidney homogenate from whole kidney (20 μg protein)
was incubated at 37°C in 50 mM sodium citrate buffer pH 5 containing 5 mM ZnCl2, 150 mM
NaCl2, 10 μM lisinopril and 0.1 mM Ang II. The enzyme reaction was terminated by addition
of 1% trifluoroacetic acid (TFA). Renin activity was measured as described before with some
modifications [59]. Kidney homogenate from whole kidney (20 μg protein) was incubated at
37°C in 50 mM MES buffer pH 6.75 containing 1 mM EDTA, 100 μM peptidase inhibitors
(thiorphan, 4-aminophosphonobutyric acid, Cpp-AAF-pAb) and 40 μM tetradecapeptide. Internal Ang peptide standards (New England Peptide, Gardner, MA or Anaspec, San Jose, CA,
USA) were added, the mixture was diluted with 90% acetonitrile containing 0.3% TFA and
spotted onto an MTP 384 ground steel target plate (Bruker Daltonics, Billerica, MA, USA).
Mass spectra were obtained using an Autoflex III smartbeam MALDI TOF/TOF instrument
(Bruker Daltonics, Billerica, MA, USA). The spectral analysis was performed with proprietary
Bruker Flex Analysis and Imaging software.

Plasma collection
Mice were sacrificed by decapitation using a rodent guillotine. Trunk blood was collected in
ice-chilled heparinized tubes. Blood was centrifuged at 10,000 x g for 10 minutes at 4°C. Plasma
was separated, aliquoted, and stored at -80°C.

Urine collection and analysis of creatinine and albumin
Mice were placed individually in metabolic cages for 24h-urine collection with free access to
food and water. Protease inhibitors (Roche Diagnostics, Indianapolis, IN, USA) were added to
prevent protein degradation. Twenty four-hour urine samples were centrifuged at 3,000 x g for
5 min at 4°C to remove debris. Urinary creatinine was measured using a kit purchased from
Quidel (San Diego, CA, USA). Urinary albumin excretion was determined using a Mouse Albumin ELISA Quantitation Set (Bethyl Laboratories, Montgomery, TX, USA). The optical density was measured at a wavelength of 450 nm using a Fusion Packard plate reader (Packard
BioScience, Meriden, CT, USA).

Plasma and urinary PRCP activity
Plasma and urinary PRCP activity were measured using the fluorogenic substrate,
7-Mca-APK(Dnp) (Biomol International, Farmingdale NY, USA) in presence of the ACE inhibitor lisinopril. Plasma (40–100 μg protein) or urine samples (4 μl, 1.3±0.1 μg creatinine)
were incubated with 100 μl of the reaction buffer containing 50 mM sodium citrate buffer pH
5, 5 mM ZnCl2, 150 mM NaCl, 10 μM lisinopril and 50 μM Mca-APK(Dnp). After incubation
at 37°C for 1 hour, fluorescence was measured at 328 nm excitation and 393 nm
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emission wavelengths using a Fusion Packard plate reader (Packard BioScience, Meriden,
CT, USA).

Data Analysis
The relative mesangial matrix area (RMMA), relative glomerular fibrosis area (RGFA) and
tubular or glomerular PRCP staining were quantified using MetaMorph image analysis
software (Molecular Devices, Inc., Sunnyvale, CA, USA). All data were expressed as mean
± SEM. Unpaired student’s t-test was used to evaluate the differences between two groups.
One-way ANOVA and post hoc Bonferroni’s Multiple Comparison Test compared the
difference between more than two groups. A value of p<0.05 was considered statistically
significant.

Results
Metabolic and cardiovascular parameters
After eleven weeks of 2K1C, the kidneys were removed and weighed. Clipped kidneys were significantly smaller and atrophic compared to the contralateral unclipped kidneys and kidneys
from control mice (Fig. 1A). As shown in Fig. 1B, a significant rise in blood pressure was observed at one and two weeks after clip placement compared with baseline. The blood pressure
returned to baseline levels from weeks three through eight after clip placement, which was followed by a significant increase in blood pressure from baseline at weeks nine, ten, and eleven.
There was a significant circadian change of blood pressure at baseline and 11 weeks after
2K1C while at 2 weeks of 2K1C the blood pressure in the 12 h light period was not
different from the 12 h dark period (Fig. 1C). A significant increase in heart rate was detected
after one week of clip placement compared to baseline (Fig. 1D). Similar to the circadian
changes of blood pressure, there was a significant difference of heart rate in the 12 h light
period compared to the 12 h dark period at baseline and 11 weeks after 2K1C (Fig. 1E).
However, at 2 weeks after 2K1C, the heart rate in the 12 h light period was not different
from the 12 h dark period (Fig. 1E). Locomotor activity was not affected by clip placement
(Fig. 1F). Circadian changes of activity indicate a significant higher locomotor activity in the
12 h dark period compared to the 12 h light period (Fig. 1G). There was a trend of increased
urinary output after clip placement (Fig. 1H) and daily urinary albumin excretion was significantly increased one week after clip placement and returned back to baseline levels during the
course of the study (Fig. 1I). The 2-week and 11-week time points were selected for
further studies.

Renal Morphology
Mesangial expansion was significantly increased in both 2K1C kidneys at 2 weeks and 11
weeks of 2K1C compared to the control kidneys; however, the unclipped kidneys had a significantly greater mesangial expansion compared to the clipped kidneys at both 2 and 11 weeks
post-clipping (Fig. 2A). The clipped and contralateral unclipped 2K1C kidneys also exhibited
significantly greater glomerular fibrosis at 2 weeks and 11 weeks of 2K1C compared to the control kidneys. The clipped kidneys showed greater glomerular fibrosis than the unclipped kidneys (Fig. 2B).

Protein expression of renal PRCP, PREP, and ACE
Renal PRCP protein expression was significantly reduced in the clipped kidneys but not in the
contralateral unclipped kidneys compared to the control kidneys at 2 and 11 weeks after 2K1C
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Fig 1. Assessment of kidney weight, blood pressure, heart rate, locomotor activity, urinary output and urinary albumin excretion. A) Kidney weights
after 11 weeks of 2K1C. *p < 0.05. B) Weekly blood pressure measurements for 11 weeks after insertion of the renal artery clip. The difference in blood
pressure between baseline and after clip placement is shown. *p < 0.001 vs. Control, **p < 0.0001 vs. Control. C) Circadian changes of blood pressure at
baseline, 2 weeks and 11 weeks after clip placement. *p < 0.05 vs. light. D) Weekly heart rate measurements for 11 weeks of 2K1C. *p < 0.001 vs. baseline
(0 weeks). E) Circadian changes of heart rate at baseline, 2 weeks and 11 weeks after clip placement. *p < 0.05 vs. light. F) Locomotor activity in mice over
11 weeks of 2K1C. G) Circadian changes of activity at baseline, 2 weeks and 11 weeks after clip placement. *p < 0.05, **p < 0.01, ***p < 0.001 vs. light. H)
Urinary output at baseline and 1, 2, 3, 4, 6, 8, and 10 weeks after clip placement. I) Daily urinary albumin excretion at baseline and 1, 2, 3, 4, 6, 8, and 10
weeks after insertion of the renal artery clip *p < 0.0001 vs. Control.
doi:10.1371/journal.pone.0117899.g001

(Fig. 3A,B). Expression of renal PREP, an alternative peptidase capable of producing Ang(1–7), was not changed in both clipped and contralateral unclipped 2K1C kidneys compared to
the control (Fig. 3C). Renal ACE expression was significantly increased in unclipped 2K1C kidneys and decreased in clipped 2K1C kidneys compared to controls (Fig. 3D,E).
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Fig 2. Histological analysis of kidney sections 2 and 11 weeks after renal artery clip placement. A) PAS staining of control, 2K1C unclipped and 2K1C
clipped kidneys 2 and 11 weeks after clip placement. B) Masson’s Trichrome staining of control, 2K1C unclipped, and 2K1C clipped kidneys 2 and 11 weeks
after clip placement. *p < 0.001 vs. Control, p** < 0.001 vs. 2 wks, #p < 0.001, $p < 0.01.
doi:10.1371/journal.pone.0117899.g002
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Fig 3. Expression of renal PRCP, PREP, ACE and renin activity 2 and 11 weeks after renal artery clip placement. A) Western Blot of renal PRCP in
control, 2K1C unclipped and 2K1C clipped groups after 2 weeks of 2K1C. B) Western Blot of renal PRCP in control, 2K1C unclipped and 2K1C clipped
groups after 11 weeks of 2K1C. C) Western Blot of renal PREP in control, 2K1C unclipped, and 2K1C clipped groups after 11 weeks of 2K1C. D) Western
Blot of renal ACE in control, 2K1C unclipped, and 2K1C clipped groups after 2 weeks of 2K1C. E) Western Blot of renal ACE in control, 2K1C unclipped, and
2K1C clipped groups after 11 weeks of 2K1C. F) Mass spectrometric analysis of renin activity in control, 2K1C unclipped, and 2K1C clipped groups. For
Western blots, protein levels were normalized to β-actin. Values are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001.
doi:10.1371/journal.pone.0117899.g003

Renal renin activity
Renin activity was determined using a MALDI-TOF-based enzyme assays in which kidney homogenates were incubated with the renin substrate tetradecapeptide. Formed Ang I (m/z 1296)
was absolutely quantified using a stable-isotope labeled peptide standard. Fig. 3F shows that
renin activity was significantly increased in clipped 2K1C kidneys compared to control and
unclipped kidneys.

Renal, urinary and plasma PRCP activity
Renal enzymatic activity of PRCP was determined using MALDI-TOF-based enzyme assays
that allow for the incubation of kidney sections or homogenates with the natural substrate Ang
II. PRCP enzymatic activity in tissue sections was determined in situ by detecting the formed
product Ang-(1–7) (Fig. 4A). Renal PRCP activity was detected predominantly in the cortex of
the unclipped, clipped, and control kidneys and was significantly reduced in the clipped kidneys compared to the control and unclipped kidneys at 2 weeks of 2K1C (Fig. 4A). The in vitro
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Fig 4. PRCP enzyme activity in control, 2K1C unclipped and 2K1C clipped groups 2 and 11 weeks after clip placement. A) MALDI imaging of Ang(1–7) formation from Ang II in control kidneys or unclipped and clipped kidney sections obtained after 2 weeks of clip placement. *p < 0.01 vs. Control. B) In
vitro enzyme activity of Ang-(1–7) formation using homogenates obtained from control kidneys or unclipped and clipped kidneys 11 weeks after renal artery
clip placement. *p < 0.01 vs. Control. C) Plasma PRCP activity at baseline and 2 or 11 weeks after clip placement. D) PRCP activity in 24-hour urine
samples at baseline and 1, 2, 3, 4, 6, 8, and 10 weeks after insertion of the renal artery clip.
doi:10.1371/journal.pone.0117899.g004

enzyme assay confirmed the results obtained with the in situ enzyme assay showing a significantly reduced PRCP activity in the clipped kidneys compared to contralateral unclipped and
control kidneys after 11 weeks of 2K1C (Fig. 4B). There was no difference in PRCP activity between the contralateral unclipped and control groups (Fig. 4A,B). Plasma and urinary PRCP
activities after clip placement were not different from baseline levels (Fig. 4C,D) although there
was a trend toward reduced urinary PRCP levels one week after clip placement and a sustained
recovery of PRCP levels during the following ten weeks.

Immunolocalization of renal PRCP
Immunofluorescence of PRCP revealed expression of the enzyme in the apical membrane of
the renal proximal tubules (Fig. 5A). Furthermore, PRCP co-localized with nephrin in the glomeruli of all groups (Fig. 5A-C). Tubular PRCP expression was reduced in clipped kidneys
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Fig 5. Immunofluorescence analysis of PRCP and nephrin at 60x magnification eleven weeks after 2K1C. White arrows indicate PRCP staining. A)
Localization of PRCP and nephrin with overlay in the control kidney. B) Localization of PRCP and nephrin with overlay in the unclipped kidney. C)
Localization of PRCP and nephrin with overlay in the clipped kidney. D) Quantitative analysis of cortical, glomerular and tubular PRCP expression in control,
unclipped and clipped kidneys. *p < 0.05 vs. Control. **p < 0.01 vs. Unclipped.
doi:10.1371/journal.pone.0117899.g005

while glomerular PRCP and nephrin expression were not affected by placement of the renal artery clip as compared with the control (Fig. 5A-C). Overall, glomerular expression of PRCP in
the clipped kidneys was unchanged compared to control kidneys and unclipped kidneys while
total cortical expression and tubule staining for PRCP was decreased (Fig. 5D).
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Discussion
In this study, the induction of renovascular hypertension caused a significant decrease in clipped
kidney weight and an immediate hypertensive response at week one after 2K1C. After one week
of clip placement, 24 h blood pressure gradually returned to baseline, showed normal levels at
week four post-clipping and increased again toward the end of the study at week 11 after 2K1C.
The 24 h heart rate also increased one week after 2K1C and returned to baseline levels during
the following ten weeks of 2K1C. Circadian changes were observed at baseline and at 11 weeks
after 2K1C. However, at two weeks after 2K1C the 12 h light period did not significantly dip
compared with the 12 h dark period although the animals maintained circadian locomotor activity. This finding suggests that, in the early phase, renovascular hypertension disrupts the circadian blood pressure and heart rate rhythm causing a non-dipping effect of the light period.
Previous studies described a gradual increase and full development of hypertension in mice
over two weeks and sustained hypertension until week four post-clipping [60–63]. Gradual and
sustained hypertension was also observed in rats after clip placement [64,65]. The present study
is one of the few studies that monitored the progression of renal artery constriction in mice for
longer than four weeks. Consistent with our results, two other studies in mice describe that
blood pressure peaked at one week after 2K1C and tended to decline in the following four weeks
after 2K1C surgery [66,67] suggesting that progressive stenosis, severe atrophy and complete
renal ischemia cause resolution of the hypertension. Similarly, one study in rats demonstrated
an immediate increase of blood pressure in the first week of 2K1C that was followed by a decline
over the following 4 weeks although levels were still significantly different from baseline at the
end of the study [68]. The discrepancies between these studies could be explained by different
degrees of renal blood flow restriction, use of other methods to measure blood pressure, the experimental approach, use of different clips and sizes, or the genetic background of the mice.
The 2K1C treatment caused renal injury in both the clipped and the contralateral unclipped
kidneys. This was seen with the increased urinary albumin excretion after clip placement although albuminuria normalized within one week of 2K1C following the same trend as observed for blood pressure and heart rate measurements. Indeed, recent studies have shown that
many patients with renal impairment are normoalbuminuric, therefore urging a search for underlying pathologies and new markers of CKD [69–72]. The initial increase of blood pressure
and urinary albumin excretion in our model may be directly dependent on hyperreninemia
and elevated Ang II production especially in the early phase when renin secretion is activated
[73] while in the chronic phase, after nine weeks of clip placement, other factors might be responsible for causing the hypertension.
Renal injury was also demonstrated by mesangial expansion and glomerular fibrosis in both
kidneys of the clipped animals; however mesangial expansion was exacerbated in the contralateral unclipped group. These renal pathologies are similar to those found in humans with renal
artery stenosis where the stenotic kidney showed ischemic changes while the contralateral kidney showed signs of glomerulosclerosis [58]. A separate clinical study involving patients with
atherosclerotic renal artery stenosis also demonstrated advanced glomerulosclerosis and similar renal morphology in the affected kidneys [74].
The progression of renovascular hypertension was associated with changes of renal PRCP
expression and activity as analyzed using Western blot and mass spectrometry. Renal PRCP expression levels were significantly lower in the clipped kidney compared to both the unclipped
and control kidneys. Similar to PRCP, renal ACE2 expression and Ang-(1–7) levels were decreased in 2K1C rats while Ang II was increased suggesting that a differential regulation of the
RAS may contribute to hypertension in this model [64]. In addition, ACE was increased in the
unclipped kidney while renin was elevated in the clipped kidney confirming previous findings
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of the RAS in animals with renovascular hypertension [75]. However, protein expression of
renal PREP, an alternative Ang-(1–7) forming peptidase, was not different between all groups.
These findings suggest that ACE, renin, PRCP and ACE2 participate in renal changes in the
2K1C model and indicate that PREP protein expression is not affected by renal pathologies induced in this model. Indeed, a previous study conducted in our laboratory using genetic deletion mouse models confirmed that the contribution of PREP to renal Ang II processing is
negligible compared to that of PRCP and ACE2 [37].
Enzymatic activity studies using established MALDI-TOF mass spectrometric methods
[37,38] support the Western blot data. PRCP enzymatic activity was significantly decreased in
the clipped kidney compared to the control and unclipped kidney. Although a trend for altered
PRCP levels in whole urine was observed, the changes were not significant most likely due to a
predominant localization of PRCP in urinary exosomes [76]. Plasma PRCP activity was not
changed. Accumulation of Ang II in the 2K1C model could be responsible for decreased renal
PRCP activity as Ang II has been shown to inhibit PRCP activity at higher concentrations [77].
To understand and characterize the role of PRCP in the renal cortex during injurious conditions protein expression patterns in the kidney were analyzed using immunofluorescence.
PRCP was localized in the renal cortex in the apical membrane of tubules and also within the
glomerulus. PRCP expression was significantly reduced in the tubules in the clipped group,
perhaps due to the severe tubulointerstitial atrophy present. Severe tubulointerstitial atrophy
was also seen in the nephrectomized, affected kidney in patients with atherosclerotic renal artery stenosis [74]. PRCP co-localized with nephrin in all groups, suggesting its expression within podocytes. Expression of nephrin was not affected by the 2K1C approach.
Localization of PRCP to renal tubules and glomeruli fits well with previous studies identifying the renal cortex as the major region in the kidney that generates Ang-(1–7) from Ang II
and expresses the Ang-(1–7) binding site [38,78]. We propose that renal Ang II can be degraded to Ang-(1–7) by PRCP in the renal cortex thereby preventing activation of cell signaling
through Ang II type I receptors. Therefore, loss of renoprotective PRCP in renovascular hypertension may contribute to progression of renal injury and exacerbate damage in the affected
kidney. As one of the primary functions of PRCP in the vasculature is the activation of prekallikrein leading to activated kallikrein and bradykinin release [50,79,80], loss of PRCP in 2K1C
could also cause decreased synthesis and secretion of renal kallikrein and thus diminished
kinin release. Indeed, the kallikrein-kinin system is reduced in patients and animals with renovascular hypertension [81–83]. Changes in kallikrein and kinin levels could be an alternative
explanation for the observed progression of hypertension and renal damage as kinins exhibit
vasodilatory effects and may afford renoprotection through AT2 and B2 receptors. Therefore,
PRCP may functionally connect the kallikrein-kinin system with the RAS and the combined
differential regulation of both systems could contribute to the pathogenesis of
renovascular hypertension.

Acknowledgments
We would like to acknowledge Dr. Valerie Neff and Mary Key for their excellent
technical assistance.

Author Contributions
Conceived and designed the experiments: NG OL MM KME. Performed the experiments: NG
OL. Analyzed the data: NG OL MM KME. Contributed reagents/materials/analysis tools: KME
MM NG. Wrote the paper: NG OL MM KME.

PLOS ONE | DOI:10.1371/journal.pone.0117899 February 23, 2015

12 / 17

PRCP in Renovascular Hypertension

References
1.

Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW et al. (2007) Prevalence of chronic kidney disease
in the United States. JAMA 298: 2038–2047. 298/17/2038 [pii]; doi: 10.1001/jama.298.17.2038 PMID:
17986697

2.

Marut W, Kavian N, Servettaz A, Hua-Huy T, Nicco C et al. (2013) Angiotensin II receptor blockade
ameliorates systemic fibrosis in the mouse. Arthritis Rheum. doi: 10.1002/art.38169 PMID: 24285000

3.

Bernstein KE, Sayeski PP, Doan T, Farmer PK, Ali MS (2001) Signal transduction pathways of angiotensin II in the kidney. Contrib Nephrol 16–33. PMID: 11705281

4.

Lavoz C, Rodrigues-Diez R, Benito-Martin A, Rayego-Mateos S, Rodrigues-Diez RR et al. (2012) Angiotensin II contributes to renal fibrosis independently of Notch pathway activation. PLoS One 7:
e40490. PONE-D-12–05960 [pii]. doi: 10.1371/journal.pone.0040490 PMID: 22792351

5.

Giani JF, Mayer MA, Munoz MC, Silberman EA, Hocht C et al. (2009) Chronic infusion of angiotensin(1–7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. Am J Physiol
Endocrinol Metab 296: E262–E271. doi: 10.1152/ajpendo.90678.2008 PMID: 19001546

6.

Ren Y, Garvin JL, Carretero OA (2002) Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension 39: 799–802. PMID: 11897767

7.

Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP et al. (2003) Angiotensin-(1–7) is an
endogenous ligand for the G protein-coupled receptor Mas 1. Proc Natl Acad Sci U S A 100:
8258–8263. PMID: 12829792

8.

Santiago NM, Guimaraes PS, Sirvente RA, Oliveira LA, Irigoyen MC et al. (2010) Lifetime overproduction of circulating Angiotensin-(1–7) attenuates deoxycorticosterone acetate-salt hypertension-induced
cardiac dysfunction and remodeling. Hypertension 55: 889–896. HYPERTENSIONAHA.110.149815
[pii]; doi: 10.1161/HYPERTENSIONAHA.110.149815 PMID: 20212262

9.

Xu P, Costa-Goncalves AC, Todiras M, Rabelo LA, Sampaio WO et al. (2008) Endothelial dysfunction
and elevated blood pressure in MAS gene-deleted mice. Hypertension 51: 574–580. HYPERTENSIONAHA.107.102764 [pii]; doi: 10.1161/HYPERTENSIONAHA.107.102764 PMID: 18180400

10.

Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S et al. (2005) Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 289: H2356–H2363. 00317.2005 [pii]; doi: 10.1152/ajpheart.00317.2005 PMID: 16024575

11.

Mercure C, Yogi A, Callera GE, Aranha AB, Bader M et al. (2008) Angiotensin(1–7) blunts hypertensive
cardiac remodeling by a direct effect on the heart. Circ Res 103: 1319–1326. CIRCRESAHA.108.184911 [pii]; doi: 10.1161/CIRCRESAHA.108.184911 PMID: 18845809

12.

Shah A, Oh YB, Lee SH, Lim JM, Kim SH (2012) Angiotensin-(1–7) attenuates hypertension in exercise-trained renal hypertensive rats. Am J Physiol Heart Circ Physiol 302: H2372–H2380.
ajpheart.00846.2011 [pii]; doi: 10.1152/ajpheart.00846.2011 PMID: 22467306

13.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M et al. (2000) A novel angiotensin-converting
enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87:
E1–E9. PMID: 10969042

14.

Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS et al. (2004) Increased ACE 2 and decreased
ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 43:
1120–1125. PMID: 15078862

15.

Ye M, Wysocki J, William J, Soler MJ, Cokic I et al. (2006) Glomerular localization and expression of
Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in
diabetes. J Am Soc Nephrol 17: 3067–3075. PMID: 17021266

16.

Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD et al. (2006) ACE and ACE2 activity in diabetic mice.
Diabetes 55: 2132–2139. PMID: 16804085

17.

Giani JF, Munoz MC, Pons RA, Cao G, Toblli JE et al. (2011) Angiotensin-(1–7) reduces proteinuria
and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am
J Physiol Renal Physiol 300: F272–F282. doi: 10.1152/ajprenal.00278.2010 PMID: 20962118

18.

Alghamri MS, Weir NM, Anstadt MP, Elased KM, Gurley SB et al. (2013) Enhanced angiotensin IIinduced cardiac and aortic remodeling in ACE2 knockout mice. J Cardiovasc Pharmacol Ther 18:
138–151. 1074248412460124 [pii]; doi: 10.1177/1074248412460124 PMID: 23043153

19.

Yamazato Y, Ferreira AJ, Hong KH, Sriramula S, Francis J et al. (2009) Prevention of pulmonary hypertension by Angiotensin-converting enzyme 2 gene transfer. Hypertension 54: 365–371. HYPERTENSIONAHA.108.125468 [pii]; doi: 10.1161/HYPERTENSIONAHA.108.125468 PMID: 19564552

20.

Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C et al. (2010) Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin IIdependent hypertension. Hypertension 55: 90–98. doi: 10.1161/HYPERTENSIONAHA.109.138420
PMID: 19948988

PLOS ONE | DOI:10.1371/journal.pone.0117899 February 23, 2015

13 / 17

PRCP in Renovascular Hypertension

21.

Feng Y, Xia H, Cai Y, Halabi CM, Becker LK et al. (2010) Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res 106: 373–382. CIRCRESAHA.109.208645 [pii]; doi: 10.1161/CIRCRESAHA.109.208645 PMID: 19926873

22.

Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP et al. (2005) Protection from angiotensin
II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol
90: 783–790. expphysiol.2005.031096 [pii]; doi: 10.1113/expphysiol.2005.031096 PMID: 16049057

23.

Bindom SM, Hans CP, Xia H, Boulares AH, Lazartigues E (2010) Angiotensin I-converting enzyme
type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 59: 2540–2548. doi:
10.2337/db09-0782 PMID: 20660625

24.

Verma A, Shan ZY, Lei B, Yuan LH, Liu X et al. (2012) ACE2 and Ang-(1–7) Confer Protection Against
Development of Diabetic Retinopathy. Molecular Therapy 20: 28–36. doi: 10.1038/mt.2011.155 PMID:
21792177

25.

Liu CX, Hu Q, Wang Y, Zhang W, Ma ZY et al. (2010) Angiotensin-Converting Enzyme 2 Overexpression Remarkably Ameliorated Glomerular Injury in a Rat Model of Diabetic Nephropathy: A Comparison
with ACE Inhibition. Mol Med. doi: 10.2119/molmed.2010.00204 PMID: 21203694

26.

Nadarajah R, Milagres R, Dilauro M, Gutsol A, Xiao F et al. (2012) Podocyte-specific overexpression
of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney Int 82:
292–303. ki201283 [pii]; doi: 10.1038/ki.2012.83 PMID: 22475818

27.

Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI et al. (2010) Angiotensin-(1–7)angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within
the cell nucleus. Hypertension 55: 166–171. HYPERTENSIONAHA.109.141622 [pii]; doi: 10.1161/
HYPERTENSIONAHA.109.141622 PMID: 19948986

28.

Monteiro MB, Senador D, Zhang WF, Morris M, Elased KM (2008) Balance of ACE and ACE2 in diabetes: Decreased renal ACE2 activity in hypertensive db/db diabetic mice. Hypertension 52: E91.

29.

Gurley SB, Allred A, Le TH, Griffiths R, Mao L et al. (2006) Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest 116: 2218–2225. 05960 [pii]. doi: 10.1172/
JCI16980 PMID: 16878172

30.

Gurley SB, Coffman TM (2008) Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed
messages. Exp Physiol 93: 538–542. doi: 10.1113/expphysiol.2007.040014 PMID: 18376006

31.

Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M et al. (2006) Deletion of angiotensin-converting
enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin
II. Hypertension 47: 718–726. PMID: 16505206

32.

Zhong J, Guo D, Chen CB, Wang W, Schuster M et al. (2011) Prevention of angiotensin II-mediated
renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension
57: 314–322. HYPERTENSIONAHA.110.164244 [pii]; doi: 10.1161/HYPERTENSIONAHA.110.
164244 PMID: 21189404

33.

Welches WR, Brosnihan KB, Ferrario CM (1993) A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase
and neprilysin. Life Science 52: 1461–1480. PMID: 8387132

34.

Tan F, Morris PW, Skidgel RA, Erdös EG (1993) Sequencing and cloning of human prolylcarboxypeptidase (angiotensinase C). Similarity to both serine carboxypeptidase and prolylendopeptidase families.
J Biol Chem 268: 16631–16638. PMID: 8344943

35.

Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM (1992) In vivo metabolism of angiotensin I by
neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 19: 692–696.
PMID: 1317352

36.

Rioli V, Kato A, Portaro FC, Cury GK, te KK et al. (1998) Neuropeptide specificity and inhibition of recombinant isoforms of the endopeptidase 3.4.24.16 family: comparison with the related recombinant
endopeptidase 3.4.24.15. Biochem Biophys Res Commun 250: 5–11. PMID: 9735321

37.

Grobe N, Weir NM, Leiva O, Ong FS, Bernstein KE et al. (2013) Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J
Physiol Cell Physiol 304: C945–C953. ajpcell.00346.2012 [pii]; doi: 10.1152/ajpcell.00346.2012 PMID:
23392115

38.

Grobe N, Elased KM, Cool DR, Morris M (2012) Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab 302: E1016–E1024. ajpendo.00515.2011
[pii]; doi: 10.1152/ajpendo.00515.2011 PMID: 22318946

39.

Yang HYT, Erdos EG, Chiang TS, Jenssen TA, Rodgers JG (1970) Characteristics of An Enzyme That
Inactivates Angiotensin Ii (Angiotensinase C). Biochemical Pharmacology 19: 1201–1211.

PLOS ONE | DOI:10.1371/journal.pone.0117899 February 23, 2015

14 / 17

PRCP in Renovascular Hypertension

40.

Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdos EG (1978) Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 253: 5927–5931. PMID:
28321

41.

Nomura M, Nomura S, Mitsui T, Suzuki M, Kobayashi H et al. (2005) Possible involvement of aminopeptidase A in hypertension and renal damage in Dahl salt-sensitive rats. Am J Hypertens 18:
538–543. S0895–7061(04)01149–5 [pii]; PMID: 15831365

42.

Yatabe J, Yoneda M, Yatabe MS, Watanabe T, Felder RA et al. (2011) Angiotensin III stimulates aldosterone secretion from adrenal gland partially via angiotensin II type 2 receptor but not angiotensin II
type 1 receptor. Endocrinology 152: 1582–1588. en.2010–1070 [pii]; doi: 10.1210/en.2010-1070
PMID: 21303953

43.

Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P et al. (1996) Identification of metabolic
pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of
angiotensin III in the control of vasopressin release. Proc Natl Acad Sci U S A 93: 11968–11973.
PMID: 8876246

44.

Fyhrquist F, Saijonmaa O (2008) Renin-angiotensin system revisited. J Intern Med 264: 224–236. doi:
10.1111/j.1365-2796.2008.01981.x PMID: 18793332

45.

Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y et al. (2001) Role of the renin-angiotensin
system in vascular diseases: expanding the field. Hypertension 38: 1382–1387. PMID: 11751722

46.

Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdos EG (1978) Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 253: 5927–5931. PMID:
28321

47.

Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman MT et al. (2011) Murine prolylcarboxypeptidase
depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 117:
3929–3937. blood-2010–11–318527 [pii]; doi: 10.1182/blood-2010-11-318527 PMID: 21297000

48.

Jeong JK, Diano S (2013) Prolyl carboxypeptidase and its inhibitors in metabolism. Trends Endocrinol
Metab 24: 61–67. S1043–2760(12)00201–9 [pii]; doi: 10.1016/j.tem.2012.11.001 PMID: 23245768

49.

Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E et al. (2009) Prolylcarboxypeptidase regulates food intake by inactivating alpha-MSH in rodents. J Clin Invest 119: 2291–2303. doi: 10.1172/
JCI37209 PMID: 19620781

50.

Shariat-Madar Z, Mahdi F, Schmaier AH (2002) Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277: 17962–17969. doi: 10.1074/jbc.
M106101200 M106101200 [pii]. PMID: 11830581

51.

Moreira CR, Schmaier AH, Mahdi F, da MG, Nader HB et al. (2002) Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett 523: 167–170.
S0014579302029800 [pii]. PMID: 12123826

52.

Odya CE, Erdos EG (1981) Human prolylcarboxypeptidase. Methods Enzymol 80 Pt C: 460–466.

53.

Adams GN, Stavrou EX, Fang C, Merkulova A, Alaiti MA et al. (2013) Prolylcarboxypeptidase promotes
angiogenesis and vascular repair. Blood. blood-2012–10–460360 [pii]; doi: 10.1182/blood-2012-12473777 PMID: 24501760

54.

Xu S, Lind L, Zhao L, Lindahl B, Venge P (2012) Plasma prolylcarboxypeptidase (angiotensinase C) is
increased in obesity and diabetes mellitus and related to cardiovascular dysfunction. Clin Chem 58:
1110–1115. clinchem.2011.179291 [pii]; doi: 10.1373/clinchem.2011.179291 PMID: 22539806

55.

Wang L, Feng Y, Zhang Y, Zhou H, Jiang S et al. (2006) Prolylcarboxypeptidase gene, chronic hypertension, and risk of preeclampsia. Am J Obstet Gynecol 195: 162–171. S0002–9378(06)00151–7 [pii];
doi: 10.1016/j.ajog.2006.01.079 PMID: 16681991

56.

Zhang Y, Hong XM, Xing HX, Li JP, Huo Y et al. (2009) E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients.
Chin Med J (Engl) 122: 2461–2465. PMID: 20079160

57.

Goldblatt H, Lynch J, Hanzal RF, Summerville WW (1934) STUDIES ON EXPERIMENTAL HYPERTENSION: I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE
BY MEANS OF RENAL ISCHEMIA. J Exp Med 59: 347–379. PMID: 19870251

58.

Cote I, Boucher D, Lebel M (2001) Renovascular hypertension and focal segmental glomerulosclerosis
in the contralateral kidney. J Hum Hypertens 15: 143–144. doi: 10.1038/sj.jhh.1001145 PMID:
11317195

59.

Elased KM, Cool DR, Morris M (2005) Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity. Hypertension 46: 953–959. PMID: 16103259

60.

Cervenka L, Horacek V, Vaneckova I, Hubacek JA, Oliverio MI et al. (2002) Essential role of AT1A receptor in the development of 2K1C hypertension. Hypertension 40: 735–741. PMID: 12411470

PLOS ONE | DOI:10.1371/journal.pone.0117899 February 23, 2015

15 / 17

PRCP in Renovascular Hypertension

61.

Cervenka L, Vaneckova I, Huskova Z, Vanourkova Z, Erbanova M et al. (2008) Pivotal role of angiotensin II receptor subtype 1A in the development of two-kidney, one-clip hypertension: study in angiotensin
II receptor subtype 1A knockout mice. Journal of Hypertension 26: 1379–1389. doi: 10.1097/HJH.
0b013e3282fe6eaa PMID: 18551014

62.

Lazartigues E, Lawrence AJ, Lamb FS, Davisson RL (2004) Renovascular hypertension in mice with
brain-selective overexpression of AT1a receptors is buffered by increased nitric oxide production in the
periphery. Circ Res 95: 523–531. doi: 10.1161/01.RES.0000140892.86313.c2 01.
RES.0000140892.86313.c2 [pii]. PMID: 15284190

63.

Pliquett RU, Benkhoff S, Jung O, Brandes RP (2014) Sympathoactivation and rho-kinase-dependent
baroreflex function in experimental renovascular hypertension with reduced kidney mass. BMC Physiol
14: 4. 1472–6793–14–4 [pii]; doi: 10.1186/1472-6793-14-4 PMID: 24946879

64.

Prieto MC, Gonzalez-Villalobos RA, Botros FT, Martin VL, Pagan J et al. (2011) Reciprocal changes in
renal ACE/ANG II and ACE2/ANG 1–7 are associated with enhanced collecting duct renin in Goldblatt
hypertensive rats. Am J Physiol Renal Physiol 300: F749–F755. ajprenal.00383.2009 [pii]; doi: 10.
1152/ajprenal.00383.2009 PMID: 21209009

65.

Qin XP, Zeng SY, Tian HH, Deng SX, Ren JF et al. (2009) Involvement of prolylcarboxypeptidase in the
effect of rutaecarpine on the regression of mesenteric artery hypertrophy in renovascular hypertensive
rats. Clin Exp Pharmacol Physiol 36: 319–324. CEP5079 [pii]; doi: 10.1111/j.1440-1681.2008.05079.x
PMID: 19018804

66.

Lorenz JN, Lasko VM, Nieman ML, Damhoff T, Prasad V et al. (2011) Renovascular hypertension
using a modified two-kidney, one-clip approach in mice is not dependent on the alpha1 or alpha2 NaK-ATPase ouabain-binding site. Am J Physiol Renal Physiol 301: F615–F621. ajprenal.00158.2011
[pii]; doi: 10.1152/ajprenal.00158.2011 PMID: 21632957

67.

Fujino T, Nakagawa N, Yuhki K, Hara A, Yamada T et al. (2004) Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest 114: 805–812. doi: 10.
1172/JCI21382 PMID: 15372104

68.

Kost CK Jr., Li P, Pfeifer CA, Jackson EK (1994) Telemetric blood pressure monitoring in benign 2-kidney, 1-clip renovascular hypertension: effect of chronic caffeine ingestion. J Pharmacol Exp Ther 270:
1063–1070. PMID: 7932154

69.

Brosius FC, Pennathur S (2013) How to find a prognostic biomarker for progressive diabetic nephropathy. Kidney Int 83: 996–998. ki201358 [pii]; doi: 10.1038/ki.2013.58 PMID: 23728003

70.

Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ (2009) Integrating albuminuria and GFR in
the assessment of diabetic nephropathy. Nat Rev Nephrol 5: 397–406. nrneph.2009.91 [pii]; doi: 10.
1038/nrneph.2009.91 PMID: 19556994

71.

Mottl AK, Kwon KS, Mauer M, Mayer-Davis EJ, Hogan SL et al. (2013) Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications 27: 123–127. S1056–8727(12)00278–4
[pii]; doi: 10.1016/j.jdiacomp.2012.09.010 PMID: 23182925

72.

Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI et al. (2010) The emerging role of
biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep 10: 37–42. doi: 10.
1007/s11892-009-0080-z PMID: 20425065

73.

Brown JJ, Davies DL, Morton JJ, Robertson JI, Cuesta V et al. (1976) Mechanism of renal hypertension. Lancet 1: 1219–1221. PMID: 58263

74.

Keddis MT, Garovic VD, Bailey KR, Wood CM, Raissian Y et al. (2010) Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant 25: 3615–3622. gfq269 [pii]; doi: 10.1093/ndt/gfq269 PMID: 20501460

75.

Navar LG, Zou L, Von TA, Tarng WC, Imig JD et al. (1998) Unraveling the Mystery of Goldblatt Hypertension. News Physiol Sci 13: 170–176. PMID: 11390784

76.

Gonzales PA, Pisitkun T, Hoffert JD, Tchapyjnikov D, Star RA et al. (2009) Large-scale proteomics and
phosphoproteomics of urinary exosomes. J Am Soc Nephrol 20: 363–379. ASN.2008040406 [pii]; doi:
10.1681/ASN.2008040406 PMID: 19056867

77.

Shariat-Madar Z, Mahdi F, Schmaier AH (2004) Recombinant prolylcarboxypeptidase activates plasma
prekallikrein. Blood 103: 4554–4561. doi: 10.1182/blood-2003-07-2510 2003–07–2510 [pii]. PMID:
14996700

78.

da Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD et al. (2010) ACE2angiotensin-(1–7)-Mas axis in renal ischaemia/reperfusion injury in rats. Clin Sci (Lond) 119: 385–394.
CS20090554 [pii]; doi: 10.1042/CS20090554 PMID: 20528771

79.

Zhu L, Carretero OA, Liao TD, Harding P, Li H et al. (2010) Role of prolylcarboxypeptidase in angiotensin II type 2 receptor-mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 56: 384–390. HYPERTENSIONAHA.110.155051 [pii]; doi: 10.1161/HYPERTENSIONAHA.110.
155051 PMID: 20606103

PLOS ONE | DOI:10.1371/journal.pone.0117899 February 23, 2015

16 / 17

PRCP in Renovascular Hypertension

80.

Zhao Y, Qiu Q, Mahdi F, Shariat-Madar Z, Rojkjaer R et al. (2001) Assembly and activation of HK-PK
complex on endothelial cells results in bradykinin liberation and NO formation. Am J Physiol Heart Circ
Physiol 280: H1821–H1829. PMID: 11247797

81.

Girolami JP, Praddaude F, Ader JL, Tran VT, Eche JP et al. (1983) Bilateral urinary kallikrein excretion
in the Goldblatt hypertensive rat. Eur Heart J 4 Suppl G: 67–72. PMID: 6363081

82.

Carretero OA, Scicli AG (1978) The renal kallikrein-kinin system in human and in experimental hypertension. Klin Wochenschr 56 Suppl 1: 113–125. PMID: 366276

83.

Hulthen UL, Lecerof H, Hokfelt B (1977) Renal venous output of kinins in patients with hypertension
and unilateral renal artery stenosis. Acta Med Scand 202: 189–191. PMID: 910636

PLOS ONE | DOI:10.1371/journal.pone.0117899 February 23, 2015

17 / 17

